Guest guest Posted August 26, 2010 Report Share Posted August 26, 2010 Here is a message from Dr. Sawyers. Whether he is your doctor or not, his knowledge about CML is undisputabily at the top of the heap. His thoughts about cost becoming a factor in treatment is very interesting. http://www.cancernetwork.com/hematologic-cancer/content/article/10165/1636076?pa\ geNumber=2 & GUID=8DC59E1F-1427-4EFF-AC52-DD957B592019 & rememberme=1#VantagePoint _________________________________ A multi-institutional group of researchers have zeroed in on a more accurate way to decipher treatment outcomes in young leukemia patients using information from a simple complete blood count test. http://www.cancernetwork.com/leukemia-lymphoma/content/article/10165/1570052 ______________________________ Doctors (Oncologists) Will Flee Medicare's Low Payments, Onerous Rules By Grace-Marie | August 13, 2010 The exodus of doctors from Medicare and likely from private practice altogether - is accelerating. The signs are undeniable: A 2008 poll by an independent Medicare commission found that 28 percent of seniors had trouble finding a primary care doctor, up from 24 percent the year before. http://www.searchmedica.com/resource.html?rurl=http%3A%2F%2Fwww.cancernetwork.co\ m%2Fall-content%2F & q=cml+-+August+2010 & c=on & ss=cancerNetworkLink & p=Convera & fr=tr\ ue & ds=0 & srid=1 ___________________________________________ " Molecular responses continue to deepen over time, and there continue to be fewer progression events and fewer deaths with nilotinib, " said ENESTnd lead investigator A. Larson, MD, a professor of medicine and director of the hematologic malignancies program at the University of Chicago. " Longer follow-up supports nilotinib as a new standard of care in patients with newly diagnosed CML. " http://www.searchmedica.com/resource.html?rurl=http%3A%2F%2Fwww.cancernetwork.co\ m%2Fchronic-myeloid-leukemia%2Fmashuptool%2FMashupTool_INSTANCE_Nqff%2F1391%2Fmu\ ltiPage%2F1 & q=cml+-+August+2010 & c=on & ss=cancerNetworkLink & p=Convera & fr=true & ds=0\ & srid=3 _____________________________________ According to a duo of ASCO 2009 presentations, some patients are not being dose escalated on imatinib prior to switching to dasatinib (Sprycel). Also, switching to dasatinib was found to be associated with more adverse events than dose escalation of imatinib. “These studies give us a window on real-world clinical practice and suggest that we need to make greater efforts to educate patients and providers on how to follow NCCN guidelines,” said the senior author of both posters, , MD, director of medical oncology at Dana-Farber Cancer Center and professor of medicine at Harvard Medical School, both in Boston. http://www.cancernetwork.com/chronic-myeloid-leukemia/content/article/10165/1430\ 990 ___________________________ Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. http://www.ncbi.nlm.nih.gov/pubmed/19884523 _________________________________ For the price of $50, you can log in and purchase the entire article. I don't know how many takers they will have at that asking price, but I thought that little teaser was certainly meant to garner your interest. by Lev Osherovich, Senior Writer Two American teams have identified new cancer stem cell–related targets in the NOTCH pathway that determine progression of late-stage CML and AML. The findings could help companies developing antagonists of NOTCH signaling, which has not previously been considered a prime target in hematological malignancies. http://www.nature.com/scibx/journal/v3/n32/full/scibx.2010.974.html FYI, Lottie Duthu Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.